Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma

Merck unveils new HIV treatment and prevention data at EACS 2025

Merck will showcase results in innovative solutions in HIV treatment and prevention

RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months

VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

India invites applications under PRIP scheme to drive pharma-medtech innovation

Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company

The Lancet Regional Health publishes pivotal phase 3 clinical study on Miqnaf

Bartronics India acquires 15% stake in Huwel Life Sciences for Rs. 50 Cr

BIL also holds an option to increase its equity stake by an additional 15%

CIDSCON 2025 emphasized a multi-faceted approach to tackle AMR

The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness